"indian-generics-industry"

Trump's 100 per cent tariff on branded drugs challenges India's pharma exporters but opens doors for growth in generics and biosimilars

Early-stage investments saw a sharp uptick in the August-October period with 101 deals worth $323 million, compared to $180 million across 75 deals in May-July, according to data by Venture Intelligence.